- Home
- PRAX vs UFCS Comparison
PRAX vs UFCS Comparison
Compare PRAX & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- UFCS
- Stock Information
- Founded
- PRAX 2015
- UFCS 1946
- Country
- PRAX United States
- UFCS United States
- Employees
- PRAX N/A
- UFCS N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- UFCS Property-Casualty Insurers
- Sector
- PRAX Health Care
- UFCS Finance
- Exchange
- PRAX Nasdaq
- UFCS Nasdaq
- Market Cap
- PRAX 599.7M
- UFCS 666.1M
- IPO Year
- PRAX 2020
- UFCS N/A
- Fundamental
- Price
- PRAX $42.34
- UFCS $28.90
- Analyst Decision
- PRAX Strong Buy
- UFCS Buy
- Analyst Count
- PRAX 11
- UFCS 2
- Target Price
- PRAX $114.73
- UFCS $30.00
- AVG Volume (30 Days)
- PRAX 279.7K
- UFCS 99.5K
- Earning Date
- PRAX 08-12-2025
- UFCS 08-05-2025
- Dividend Yield
- PRAX N/A
- UFCS 2.22%
- EPS Growth
- PRAX N/A
- UFCS N/A
- EPS
- PRAX N/A
- UFCS 2.54
- Revenue
- PRAX $8,122,000.00
- UFCS $1,288,423,000.00
- Revenue This Year
- PRAX N/A
- UFCS $11.31
- Revenue Next Year
- PRAX $6,358.50
- UFCS $10.61
- P/E Ratio
- PRAX N/A
- UFCS $11.25
- Revenue Growth
- PRAX 270.02
- UFCS 14.59
- 52 Week Low
- PRAX $26.70
- UFCS $18.04
- 52 Week High
- PRAX $91.83
- UFCS $31.70
- Technical
- Relative Strength Index (RSI)
- PRAX 54.36
- UFCS 59.95
- Support Level
- PRAX $41.64
- UFCS $27.82
- Resistance Level
- PRAX $44.99
- UFCS $29.19
- Average True Range (ATR)
- PRAX 2.55
- UFCS 0.63
- MACD
- PRAX -0.11
- UFCS 0.04
- Stochastic Oscillator
- PRAX 51.07
- UFCS 87.66
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.